The global mycoplasma testing market is expected to reach USD 943.4 million by 2022, at a CAGR of 12.5% from 2017 to 2022. The major factors driving this market are the increasing growth of government support for pharmaceutical and biotechnology industries, rising R&D activities in life sciences research, and rising cell culture contamination. On the other hand, the growth of this market is hindered to some extent due to the stringent regulatory framework & time-consuming approval processes and the high degree of consolidation which acts as an entry barrier for new companies.
Mycoplasma testing market to register the highest CAGR during the forecast period
On the basis of products, the mycoplasma testing market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to grow at a higher rate during the forecast period. This is attributed to the frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques.
Pharmaceutical and biotechnology companies to dominate the mycoplasma testing market during the forecast period
Based on end users, the mycoplasma testing market is segmented into pharmaceutical and biotechnology companies, academic research institutes, contract research organizations (CROs), cell banks, and other end users. In 2017, pharmaceutical and biotechnology companies segment is expected to command the largest share and is estimated to grow at the fastest rate as compared to the other segments. This can be attributed to the increasing R&D investments in the pharmaceutical industry.
Asia is estimated to be the fastest growing regional segment in the global mycoplasma testing market during the forecast period
Geographically, the mycoplasma testing market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The Asia region is estimated to grow at the fastest rate which can be attributed to the increasing government investments in pharmaceutical R&D and the increasing trend of pharmaceutical outsourcing.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type - Tier 1 – 37%, Tier 2 – 47%, Tier 3-16%
• By Designation – C level – 46%, Director level – 36%, Others – 18%
• By Region – North America - 26%, Europe – 30%, APAC – 22%, South America – 13% and Middle East & Africa: 9%
The key players in the market are Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.), InvivoGen (U.S.), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd., WuXi AppTec (U.S.), Norgen Biotek Corp. (Canada), Agilent Technologies (U.S.), Biotools, B & M Labs, S.A (Spain), Eurofins Scientific (Luxembourg), Gibraltar Laboratories (U.S.), GeneCopoeia, Inc. (U.S.), GenBio (Canada), Hylabs (Israel), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (U.S.), Sartorius AG (Germany), Savyon Diagnostics (Israel), and ScienCell Research Laboratories, Inc. (Canada).
The report analyses the mycoplasma testing market by product, technique, application, end user, and region. Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.
Key benefits of buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the mycoplasma testing market
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the mycoplasma testing market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the mycoplasma testing market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various mycoplasma testing products across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the mycoplasma testing market